KRAS and pancreatic intraductal papillary-mucinous neoplasm: Our study specifically targeted hotspot mutations present in KRAS (G12A, G12C, G12D, G12R, G12S, G12V and G13D) and GNAS (R201C) genes, which allow for highly sensitive and quantitative detection methods in IPMN patients [10, 13].